1. Home
  2. DMAC vs ALT Comparison

DMAC vs ALT Comparison

Compare DMAC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.62

Market Cap

352.4M

Sector

Health Care

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.51

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMAC
ALT
Founded
2000
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
352.4M
421.5M
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
DMAC
ALT
Price
$6.62
$3.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$15.50
$17.67
AVG Volume (30 Days)
209.9K
2.5M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
$500,000.00
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$3.34
$2.87
52 Week High
$10.42
$7.73

Technical Indicators

Market Signals
Indicator
DMAC
ALT
Relative Strength Index (RSI) 45.13 51.91
Support Level $6.56 $3.40
Resistance Level $7.36 $3.54
Average True Range (ATR) 0.48 0.17
MACD 0.05 0.07
Stochastic Oscillator 51.14 96.32

Price Performance

Historical Comparison
DMAC
ALT

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: